オクラホマにおける急性骨髄性白血病の臨床試験
オクラホマ内の拠点で、急性骨髄性白血病に関する14件の研究が参加者を募集しています。
オクラホマ内の都市
公式研究テキスト（英語）
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Hospital Oklahoma City, Oklahoma City
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/28更新 · NCT05554393MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT05564390Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06317649Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06672146Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳〜59歳 · 全性別 · 2026/09/22更新 · NCT05554406A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第3相
6 Months – 21 Years · 全性別 · 2026/09/17更新 · NCT04293562A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第1相
18歳〜75歳 · 全性別 · 2026/08/25更新 · NCT05886049The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第1/2相
22歳以下 · 全性別 · 2026/08/25更新 · NCT04726241Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- OU Health Stephenson Cancer Center, Oklahoma City
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- University of Oklahoma Health Science Center, Oklahoma City
被験者募集中観察研究
全年齢 · 全性別 · 2026/07/06更新 · NCT01351545Pilot Imaging Study of Leukemia
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第1相
4歳〜80歳 · 全性別 · 2026/04/23更新 · NCT03633955A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- OU Health Stephenson Cancer Center, Oklahoma City
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
- University of Oklahoma Health Sciences Center, Oklahoma City
被験者募集中第2相
18歳以上 · 全性別 · 2024/05/29更新 · NCT04905810ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。